Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: Planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

The Lancet Infectious Diseases

Volumn 12, Issue 2, 2012, Pages 111-118

  Van Lunzen, Jan ^a   Maggiolo, Franco ^b   Arribas, José R ^c   Rakhmanova, Aza ^d   Yeni, Patrick ^e   Young, Benjamin ^f,g   Rockstroh, Jürgen K ^h   Almond, Steve ⁱ   Song, Ivy ^j   Brothers, Cindy ^k   Min, Sherene ^k  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b OSPEDALI RIUNITI   (Italy)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Botkin Hospital   (Russian Federation)

^e BICHAT HOSPITAL   (France)

^f Rocky Mountain CARES/DIDC   (United States)

^g Health Connections International   (Netherlands)

^h UNIVERSITY OF BONN   (Germany)

ⁱ GLAXOSMITHKLINE   (Canada)

^j GLAXOSMITHKLINE   (United States)

^k Research Triangle Park   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

ABNORMAL DREAMING; ABSCESS; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BRONCHITIS; BURKITT LYMPHOMA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPEPSIA; EPIDIDYMITIS; FATIGUE; FEMALE; FEVER; FOOT FRACTURE; FRANCE; GERMANY; HEADACHE; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERKALEMIA; INSOMNIA; INTERACTIVE VOICE RESPONSE SYSTEM; ITALY; JOINT DISLOCATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROSYPHILIS; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; RNA VIRUS; RUSSIAN FEDERATION; SIDE EFFECT; SINGLE DRUG DOSE; SPAIN; SUICIDE ATTEMPT; TREATMENT FAILURE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNITED STATES; VIRUS LOAD; WRIST FRACTURE;

ADULT; AGED; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION; YOUNG ADULT;

EID: 84856226017     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70290-0     Document Type: Article

References (22)

1. Pommier Y, Johnson A, Marchand C Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005, 4:236-248.
2. Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1 infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010, 55:39-48.
3. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359:339-354.
4. Merck reports initial results of phase III study of ISENTRESS® (raltegravir) investigational once-daily dosing in treatment-naïve adult patients infected with HIV-1 Merck, (accessed May 31, 2011). http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2010_1129.html.
5. Eron J, Rockstroh J, Reynes J, et al. QDMRK, a phase III study of the safety and efficacy of once-daily vs twice daily RAL in combination therapy for treatment-naïve HIV-infected patients. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; February 27-March 2, 2011. Abstr 150LB.
6. Klibanov O Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs 2009, 10:190-200.
7. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011, 55:813-821.
8. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010, 54:254-258.
9. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011, 25:1737-1745.
10. Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011, 55:4552-4559.
11. Hare S, Smith SJ, Métifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011, 80:565-572.
12. Eron J, Durant J, Poizot-Martin I, et al. Activity of next generation integrase inhibitor (INI) S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961). 18th International AIDS Conference; Vienna, Austria; July 18-23, 2010. Abstr MOAB0105.
13. Eron J, Kumar P, Lazzarin A, et al. DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING study cohort II. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; February 27-March 2, 2011. Abstr 151LB.
14. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval; October 2002 US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, (accessed 31 May 2011). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf.
15. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007, 46:125-133.
16. Burgess E, Blair A, Krichman K, Cutler RE Inhibition of renal creatinine secretion by cimetidine in humans. Ren Physiol 1982, 5:27-30.
17. Kastrup J, Petersen P, Bartram R, Hansen JM The effect of trimethoprim on serum creatinine. Br J Urol 1985, 57:265-268.
18. Koteff J, Borland J, Chen S, et al. An open label, placebo-controlled study to evaluate the effect of dolutegravir (DTG, S/GSK1349572) on iohexol and para-aminohippurate clearance in healthy subjects. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Sept 17-21, 2011. Abstr A1-1728.
19. Sustiva package insert Bristol-Myers Squibb, (accessed Oct 14, 2011). http://packageinserts.bms.com/pi/pi_sustiva.pdf.
20. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369:1261-1269.
21. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007, 21:2315-2321.
22. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010, 201:814-822.